Table 4.
Control | β1-Defensin (ΔCt±1 SD) | β2-Defensin (ΔCt±1 SD) |
---|---|---|
IPEC-J2 untreated cells | 6.3±0.3 | 13.9±1.5 |
Treatment/indirect effects | ||
IPEC-J2+tonsil supernatant | 6.4±0.15 | 13.5±1.2 |
IPEC-J2+tonsil supernatant+rIFN-α 100 UI/mL | 7.5±0.05*** | 13.8±1.3 |
IPEC-J2+tonsil supernatant+rIFN-α 1 UI/mL | 6.6±0.2 | 14.1±1.5 |
Treatment/direct effects | ||
IPEC-J2+rIFN-α 100 UI/mL+LPS 1 μg/mL | 10.5±0.4*** | 15.3±1.9 |
IPEC-J2+rIFN-α 1 UI/mL+LPS 1 μg/mL | 9.1±0.5** | 15.2±0.6 |
IPEC-J2+rIFN-α 100 UI/mL+LPS 2 μg/mL | 11±0.2*** | 16.4±1.7 |
IPEC-J2+rIFN-α 1 UI/mL+LPS 2 μg/mL | 8.6±0.07* | 16±0.2 |
IPEC-J2+rIFN-α 100 UI/mL+LPS 4 μg/mL | 10.8±0.01*** | 16.3±1.2 |
IPEC-J2+rIFN-α 1 UI/mL+LPS 4 μg/mL | 8.7±0.07* | 15.5±0.7 |
IPEC-J2 cells were submitted to the indicated treatments for 18 h at 37°C. Total RNA was extracted to evaluate the expression of β2 and β1-defensin genes by reverse-transcription Real-time PCR. Results are shown in terms of ΔCt±1 standard deviation. Asterisks indicate significant differences with regard to untreated cells (one-way ANOVA for repeated measures).
P<0.001.
P<0.01.
P<0.05.